[ARWR] Arrowhead Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.59 Change: 0.22 (16.06%)
Ext. hours: 1.59 Change: 0 (0%)

chart ARWR

Refresh chart

Strongest Trends Summary For ARWR

ARWR is in the medium-term up 147% in 2 years. In the long-term up 155% above S&P in 2 years and up 2616% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company?s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-dr

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.89 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0% Sales Growth - Q/Q-74.27% P/E-1.79
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-52.54% ROE-59.17% ROI-56.98%
Current Ratio9.1 Quick Ratio Long Term Debt/Equity0.01 Debt Ratio0.09
Gross Margin Operating Margin-29638.3% Net Profit Margin-28158.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities210 K Cash From Investing Activities4.3 M Cash From Operating Activities-40.57 M Gross Profit
Net Profit-28.68 M Operating Profit-29.63 M Total Assets162.38 M Total Current Assets120.15 M
Total Current Liabilities13.21 M Total Debt870 K Total Liabilities17.63 M Total Revenue40 K
Technical Data
High 52 week29.98 Low 52 week10.74 Last close29.05 Last change-0.31%
RSI44.77 Average true range1.24 Beta0.59 Volume4.6 M
Simple moving average 20 days0.31% Simple moving average 50 days5.31% Simple moving average 200 days51.5%
Performance Data
Performance Week-0.24% Performance Month10.5% Performance Quart48.9% Performance Half85.5%
Performance Year80.21% Performance Year-to-date133.9% Volatility daily2.62% Volatility weekly5.86%
Volatility monthly12.01% Volatility yearly41.59% Relative Volume448.74% Average Volume2.07 M
New High New Low

News

2020-05-28 07:30:00 | Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences

2020-05-24 10:10:00 | Is Arrowhead Pharmaceuticals a Buy?

2020-05-22 11:34:00 | Arrowhead Pharmaceuticals Is Likely to See a Trading Range Market Ahead

2020-05-19 07:02:19 | Will Arrowhead Pharmaceuticals Be a Biotech Winner?

2020-05-10 08:20:32 | Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

2020-05-08 22:38:42 | Edited Transcript of ARWR earnings conference call or presentation 7-May-20 8:30pm GMT

2020-05-08 21:30:24 | Arrowhead Pharmaceuticals, Inc ARWR Q2 2020 Earnings Call Transcript

2020-05-07 16:00:00 | Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results

2020-05-01 16:00:00 | Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences

2020-05-01 16:00:00 | Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given

2020-04-30 07:52:00 | Is Arrowhead Pharmaceuticals Close to a Cure for HBV?

2020-04-22 07:30:00 | Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results

2020-04-20 06:31:44 | Arrowhead Pharmaceuticals' NASDAQ:ARWR Incredible 2370% Share Price Run Shows What Is Possible With Stocks

2020-04-10 07:30:00 | Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis

2020-04-06 18:26:17 | Alnylam, Dicerna Join Forces to Take on Arrowhead

2020-04-06 10:30:48 | Former gene-silencing rivals bury the hatchet with new partnership

2020-03-20 14:15:35 | Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. ARWR

2020-03-18 20:00:10 | Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Mammoth Energy, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm

2020-03-17 16:10:00 | Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus COVID-19 Spread

2020-03-17 16:10:00 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635c4

2020-03-15 08:30:28 | Is Arrowhead Pharmaceuticals, Inc.'s NASDAQ:ARWR CEO Salary Justified?

2020-03-10 16:16:39 | Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Zuora, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm

2020-03-03 07:30:00 | Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH

2020-03-02 16:00:00 | Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences

2020-02-13 16:47:18 | Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zuora, Arrowhead Pharmaceuticals, ResMed, and Covetrus and Encourages Investors to Contact the Firm

2020-02-07 09:36:02 | Should First Trust Mid Cap Growth AlphaDEX ETF FNY Be on Your Investing Radar?

2020-02-06 07:47:50 | The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

2020-02-06 01:17:16 | Edited Transcript of ARWR earnings conference call or presentation 5-Feb-20 9:30pm GMT

2020-02-05 16:00:00 | Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

2020-02-05 16:00:00 | Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results

2020-02-05 07:43:12 | The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

2020-02-03 13:06:06 | Arrowhead ARWR to Report Q1 Earnings: What's in the Cards?

2020-01-24 05:31:35 | Is Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR A Volatile Stock?

2020-01-22 16:29:54 | Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?

2020-01-22 07:30:00 | Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results

2020-01-21 16:30:06 | Why This Top-Notch Biotech Stock Just Plunged By Double Digits

2020-01-16 15:55:00 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Arrowhead Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

2020-01-11 08:00:55 | Vertex, Dexcom, Insulet, Intuitive Surgical In Buy Range Before Healthcare Conference

2020-01-11 08:00:55 | These Four Stocks Are In Buy Range Before Key Healthcare Conference

2020-01-10 11:51:43 | 3 Biotech Stocks to Bank on for Buyouts in 2020

2020-01-06 07:30:00 | Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer

2020-01-02 08:00:28 | Biotech Stocks Are On Fire — Who's Leading The Profit Pack For 2020?

2019-12-27 18:06:44 | Best Stocks 2019: Innovation, As Usual, Wins The Day — Or Even The Year

2019-12-26 05:27:10 | Should First Trust Mid Cap Growth AlphaDEX Fund FNY Be on Your Investing Radar?

2019-12-24 10:00:00 | What was the top stock of 2019? And should it be in your retirement account?

2019-12-23 10:21:00 | Arrowhead Pharma Investors Should Aim for Taking Profits

2019-12-23 08:00:01 | Should You Invest in the Invesco S&P SmallCap Health Care ETF PSCH?

2019-12-20 07:30:00 | Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

2019-12-16 16:15:00 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635c4

2019-12-16 07:30:00 | Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease